Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.22.2.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents [note 6] $ 18,197 $ 43,022
Grant receivable [note 3] 145 153
Prepaid expenses and other assets 2,615 1,419
Total current assets 20,957 44,594
Right-of-use assets [note 9] 18 64
Other assets and restricted cash [note 6] 239 183
License agreement [note 4 and 5] 1,475 1,641
Goodwill [note 5] 1,034 1,034
Total assets 23,723 47,516
Current liabilities:    
Accounts payable 412 841
Accrued liabilities other 539 348
Accrued clinical liabilities 4,552 1,352
Accrued compensation 1,390 1,940
Current portion of long-term obligations [note 9] 23 69
Total current liabilities 6,916 4,550
Convertible debt [note 7] 15,763 14,920
Long-term obligations [note 9]   4
Total liabilities 22,679 19,474
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,710,747 issued and outstanding at September 30, 2022 and 9,453,542 issued and outstanding at December 31, 2021 79 79
Additional paid-in capital 125,665 121,545
Accumulated deficit (124,704) (93,586)
Accumulated other comprehensive income 4 4
Total stockholders' equity 1,044 28,042
Total liabilities and stockholders' equity 23,723 47,516
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value